www.klinickafarmakologie.cz / Klin Farmakol Farm. 2026;40(1):47-55 / KLINICKÁ FARMAKOLOGIE A FARMACIE 55 PŘEHLEDOVÉ ČLÁNKY Interval QT, etiopatogeneze arytmie „torsade de pointes“ a riziková farmakoterapie combination therapies with a correction-free and heart rate-free method. Scientific Reports. 2019;9(1):883. 54. Buckingham R. Martindale. The complete drug reference. 40th edition. London (UK): Pharmaceutical Press; 2020. 55. Traebert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Expert Opin Drug Saf. 2005;4(3):421-431. 56. Bouchaud O, Imbert P, Touze JE, et al. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J. 2009;8:289. 57. Millat-Martínez P, Salman S, Moore BR, et al. Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine. Antimicrob Agents Chemother. 2022;66(8):e0018522. 58. Esposito S, Bianchini S, Blasi F. Bedaquiline and delamanid in tuberculosis. Expert Opin Pharmacother. 2015;16(15):2319-2330. 59. Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5). 60. Kwon YS, Jeong BH, Koh WJ. Delamanid when other anti- -tuberculosis-treatment regimens failed due to resistance or tolerability. Expert Opin Pharmacother. 2015;16(2):253-261. 61. Anand AB, Malur K, Sabnis GR, et al. A case series of drug-induced torsades de pointes in patients on multidrug-resistant tuberculosis treatment: Beware the gift that conceals a blade. Heart Rhythm O2. 2024;5(5):324-326. 62. Le Blaye I, Donatini B, Hall M, et al. Acute overdosage with thioridazine: a review of the available clinical exposure. Vet Hum Toxicol. 1993;35(2):147-150. 63. Isbister GK, Balit CR, Macleod D, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol. 2010;30(4):391-395. 64. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687-693. 65. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol. Am J Ther. 2003;10(1):58-60. 66. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology. 2007;107(4):531-536. 67. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg. 1994;79(5):983-986. 68. Tampi RR, Balderas M, Carter KV, et al. Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics. 2015;56(1):36-43. 69. Kumar S, Gayle JA, Mogalapalli A, et al. Escitalopram Induced Torsade de Pointes and Cardiac Arrest in a Patient With Surgically Treated Mitral Valve Prolapse. Cureus. 2020;12(12):e11960. 70. Lingyan G, Dongdong Z, Sang G, et al. Escitalopram-induced prolongation of QT interval and Torsades de Pointes. Adverse Drug Reactions Journal. 2020;22(12):695-696. 71. de Meester A, Carbutti G, Gabriel L, et al. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258-261. 72. Khederlou H, Azimi Pirsaraei V. Torsades de Pointe Associated with Trazodone Consumption Case Rep Crit Care. 2024;2024:5759229. 73. Giroski L, Shih R. QTC Prolongation and Torsades in Bupropion Overdoses Presenting to United States Emergency Departments. Journal of Emergency Medicine. 2012;43(5):934-935. 74. Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003; 37(7-8):999-1002. 75. Raffa RB, Burmeister JJ, Yuvasheva E, et al. QTc interval prolongation by d-propoxyphene: what about other analgesics? Expert Opin Pharmacother. 2012;13(10):1397-1409. 76. Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77(2):205-223. 77. Alinejad S, Kazemi T, Zamani N, et al. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577-600. 78. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280-1287. 79. Duthie DJ, McLaren AD, Nimmo WS. Pharmacokinetics of fentanyl during constant rate i.v. infusion for the relief of pain after surgery. Br J Anaesth. 1986;58(9):950-956. 80. Cicci JD, Jagielski SM, Clarke MM, et al. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report. Eur Heart J Case Rep. 2019;3(4):1-6. 81. Marzec LN, Katz DF, Peterson PN, et al. Torsade de Pointes Associated with High-dose Loperamide Ingestion. J Innov Card Rhythm Manag. 2015;6(1):1897-1999. 82. Cirillo I, Ariyawansa J, Ali SR, et al. Effect of loperamide on heart rhythm: Randomized, double-blind, controlled study in healthy adults. JAPhA Pharmacotherapy. 2024;1(3):100006. 83. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295-316. 84. Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, et al. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol. 2020;99(9):1989-2007. 85. Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol. 2019;1(2):172-178. 86. Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. 87. Kang D, Ludwig E, Jaworowicz D, et al. Concentration- -QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2021;87(4):513-523. 88. Loffi M, Toffetti L, Gianni C, et al. Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes. J Cardiovasc Electrophysiol. 2015;26(7):811-813. 89. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. 90. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29(15):2052-2059. 91. Shetty N, Gupta S. Eribulin drug review. South Asian J Cancer. 2014;3(1):57-59. 92. Fostvedt LK, Shaik N, Martinelli G, et al. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. Expert Rev Clin Pharmacol. 2021;14(7):927-935. 93. Vogel CL, Johnston MA, Capers C, et al. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer. 2014;14(1):1-9. 94. Flatman PW, Lew VL. The magnesium dependence of sodium-pump-mediated sodium-potassium and sodium-sodium exchange in intact human red cells. J Physiol. 1981;315:421-446. 95. Apell HJ, Hitzler T, Schreiber G. Modulation of the Na,K-ATPase by Magnesium Ions. Biochemistry. 2017;56(7):1005-1016. 96. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011;124(20):2181-2184. 97. Khatib R, Sabir FRN, Omari C, et al. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452-458. 98. Magyar J, Horváth B, Bányász T, et al. L-364,373 fails to activate the slow delayed rectifier K+ current in canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(1):85-89. 99. Short B. A range of activators for cardiac IKs channels J Gen Physiol. 2020;152(2). 100. Corici C, Kohajda Z, Kristóf A, et al. L-364,373 (R-L3) enantiomers have opposite modulating effects on IKs in mammalian ventricular myocytes. Can J Physiol Pharmacol. 2013;91(8):586-592. Využíváme systém CrossRef. S články můžete snadno pracovat díky jednoznačnému identi kátoru DOI. S NÁMI SE NEZTRATÍTE Časopis je indexován v databázích Scopus a Embase
RkJQdWJsaXNoZXIy NDA4Mjc=